Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S V Rajkumar

Showing results (151-160 of 172) with videos related to

Pageof 18
Sort By:
Leukemia|May 22, 2021
Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial designI Vaxman, S K Kumar, F Buadi, et al.
Blood Cancer Journal|September 2, 2017
Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Blood Cancer Journal|August 15, 2015
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibS K Kumar, B LaPlant, V Roy, et al.
Leukemia|September 10, 2010
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)M Q Lacy, S R Hayman, M A Gertz, et al.
Leukemia|December 2, 2016
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment categoryE Muchtar, A Dispenzieri, S K Kumar, et al.
Leukemia|July 27, 2016
Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progressionW I Gonsalves, S V Rajkumar, A Dispenzieri, et al.
Blood Cancer Journal|December 8, 2021
"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experienceI Vaxman, J Abeykoon, A Dispenzieri, et al.
Leukemia|July 30, 2011
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group studyS K Kumar, J H Lee, J J Lahuerta, et al.
Leukemia|September 19, 2017
Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chainsS Sidana, N Tandon, A Dispenzieri, et al.
Leukemia|November 5, 2004
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaA Dispenzieri, G A Wiseman, M Q Lacy, et al.
Pageof 18

Showing results (151-160 of 172) with videos related to

Sort By:
Pageof 18
Leukemia|May 22, 2021
Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial designI Vaxman, S K Kumar, F Buadi, et al.
Blood Cancer Journal|September 2, 2017
Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Blood Cancer Journal|August 15, 2015
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibS K Kumar, B LaPlant, V Roy, et al.
Leukemia|September 10, 2010
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)M Q Lacy, S R Hayman, M A Gertz, et al.
Leukemia|December 2, 2016
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment categoryE Muchtar, A Dispenzieri, S K Kumar, et al.
Leukemia|July 27, 2016
Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progressionW I Gonsalves, S V Rajkumar, A Dispenzieri, et al.
Blood Cancer Journal|December 8, 2021
"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experienceI Vaxman, J Abeykoon, A Dispenzieri, et al.
Leukemia|July 30, 2011
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group studyS K Kumar, J H Lee, J J Lahuerta, et al.
Leukemia|September 19, 2017
Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chainsS Sidana, N Tandon, A Dispenzieri, et al.
Leukemia|November 5, 2004
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaA Dispenzieri, G A Wiseman, M Q Lacy, et al.
Pageof 18